Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

LAS VEGAS, NV / ACCESSWIRE / / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events ...

About ADARx Pharmaceuticals ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide ...

More than 8,000 healthcare professionals will descend on San Francisco starting Monday for the 43rd annual J.P. Morgan ...

Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney Disease Plans to Initiate Rare Kidney Diseases Cohort in Early 2025 Company to Attend 43rd Annual J.P. Morgan ...

J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.